3 February 2021

How do people with reduced immunity, especially kidney patients, react to a COVID-19 vaccination? And how can patients with peripheral arterial disease be helped by DNA testing? Two different studies at the Radboudumc will try to find answers to these two questions. These studies are made possible by ZonMw.

COVID-19 vaccination in people with impaired immune system

Researchers Renate van der Molen, theme Inflammatory diseases and Dimitri Diavatopoulos, theme Infectious diseases and global health and Marije Baas and Luuk Hilbrands, both theme Renal disorders are going to collaborate with all the Dutch umc's to study the safety and efficacy of the corona vaccine for people with impaired immune system. ZonMw has made a sum of 3.2 million euros available for this. The study in which the Radboudumc participates, the RECOVAC study (led by UMC Groningen), looks at kidney patients. For them, COVID-19 is extra dangerous and an effective and safe vaccine is of great importance. Vaccine developers' clinical trials have almost never not included patients with severe renal failure and transplant patients. Therefore, two issues are now being investigated. Firstly, the immune system response and the clinical course after vaccination in patients with severe kidney damage (kidney function less than 30 percent), in dialysis patients and in kidney transplant patients. In addition, the long-term efficacy and side effects of the vaccines in a group of dialysis and kidney transplant patients will be investigated.

Better prescription of blood thinners based on DNA research in patients with peripheral arterial vascular disease

Physician-researchers and PhD candidates Loes Willems and Josephine Kranendonk will initiate the GENPAD study together with vascular and transplant surgeon Michiel Warlé, also principal investigator. For the GENPAD study, they have received a grant of 600K euros from ZonMw. The GENPAD study is a study into better prescription of blood thinners on the basis of DNA research in patients with peripheral arterial disease (arteriosclerosis of the legs). Peripheral arterial vascular disease increases the risk of heart attack, stroke and other cardiovascular diseases. To prevent these complications as much as possible, patients are routinely prescribed a blood thinner, the drug Clopidogrel. In patients with certain DNA changes, Clopidogrel works less well. The GENPAD study will see whether patients suffer fewer complications if the treatment with the blood thinner is adapted to the results of the patient's DNA test. Should this treatment lead to better results, the study will also look at whether this method is cost-effective. This will possibly lead to changes in the current guidelines.

 

Related news items


RIMLS awards call for nominations

19 October 2021

RIMLS awards several prizes to stimulate and honor our (young) researchers. Upcoming awards are Supervisor of the Year, Best Master Thesis, Best Publication, Best Image and more. Send your nominations now before 24 November 2021.

read more

RIMLS online award ceremony proudly presenting the winners

13 January 2021

In this special webinar of the RIMLS New Year Celebration, scientific director René Bindels reviewed 2020 and looked forward to 2021. But more importantly a number of researchers received prizes in the traditional RIMLS awards ceremony. 

read more

New insight into the effect of hydroxychloroquine undermines its use in corona

11 June 2020

Researchers at Radboud university medical center have discovered an as yet unknown effect of hydroxychloroquine. Raphael Duivenvoorden was interviewed in the program Op1 at NPO1 to elaborate on the findings. It seems unlikely that chloroquine has beneficial effect in corona infections.

read more

RIMLS PhD retreat registration is open

23 January 2020

Yearly, RIMLS PhD candidates gather for the two-day PhD Retreat. Apart from the science, this event is highly valued for the opportunity to meet and get to know fellow PhD candidates during the social activities. Early bird registration and abstract submission deadline: 4 March 2020.

read more

RIMLS awards festival Twelve winners

16 January 2019

In 5 categories RIMLS young researchers received an award and bonus during the New Year's drinks. See all photo's.

read more

Report of the 12th New Frontiers symposium Better care, network care? - 2 November 2018

7 November 2018

No easy answers at this symposium last Friday, only challenges that can be overcome if we succeed in 5 things. First and most radically, put patients in the center of healthcare. Second, start with assessing what the local population needs and not what local professionals have to offer.

read more